Cargando…
The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension: Protocol for a systemic review and network meta-analysis
BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disease and ultimately leads to right heart failure. Endothelin receptor antagonists (ERAs) have been demonstrated to significantly improve prognosis in PAH. However, ERAs-induced side effects can result in poor patient tolerance. Th...
Autores principales: | Gu, Zhi-Chun, Zhang, Yi-Jing, Pan, Mang-Mang, Zhang, Chi, Liu, Xiao-Yan, Wei, An-Hua, Su, Ying-Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882387/ https://www.ncbi.nlm.nih.gov/pubmed/29538209 http://dx.doi.org/10.1097/MD.0000000000010122 |
Ejemplares similares
-
The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis
por: Kuang, Hong-Yu, et al.
Publicado: (2018) -
Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis
por: Zhang, Huijun, et al.
Publicado: (2016) -
Diffuse Pulmonary Arteriovenous Fistulas With Pulmonary Arterial Hypertension: Case Report and Review
por: Jiang, Rong, et al.
Publicado: (2016) -
QRS-T angle as a predictor of pulmonary arterial hypertension: A review
por: Li, Bo, et al.
Publicado: (2023) -
Potential mechanisms and serum biomarkers involved in sex differences in pulmonary arterial hypertension
por: Li, Chan, et al.
Publicado: (2020)